Agios' Mitapivat Phase 3 Data Reveals Significant Reduction in Sickle Cell Transfusion Burden
AGIO sits 32% above its 52-week low of $22.24.
Summary
Agios Pharmaceuticals presented new, detailed Phase 3 RISE UP trial results for mitapivat in sickle cell disease at EHA 2026. The data showed a clinically meaningful 41.1% relative reduction in patients requiring blood transfusions and a 55.9% relative reduction in average red blood cell units transfused compared to placebo. Hemoglobin responders also experienced reductions in pain crises and hospitalizations. This follows the company's May 12th announcement of upcoming data presentation and strengthens the profile of mitapivat, which is already approved for thalassemia in Europe. These new analyses highlight the drug's potential to address a critical unmet need for sickle cell patients.
At the time of this announcement, AGIO was trading at $29.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $22.24 to $46.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.